Affiliation:
1. Department of Pharmacy UC San Diego Health San Diego California USA
2. Division of Gastroenterology and Hepatology, Department of Medicine UC San Diego Health La Jolla California USA
Abstract
Co‐administration of hepatitis C virus (HCV) direct‐acting antivirals (DAAs) with anti‐epileptics or mood stabilizers with cytochrome P450 (CYP) and/or drug transport‐inducing properties is contraindicated due to concerns of subtherapeutic DAA levels that can lead to treatment failure and viral resistance. The recommended strategy is to change the interacting medication to a different agent that does not have inducing properties, but this is not always possible depending on the clinical scenario. We report on three patients who received DAAs for their HCV infection while remaining on the contraindicated anti‐epileptic or mood stabilizer by utilizing CYP and drug transport inhibitors as pharmacokinetic enhancers to attempt to overcome the induction effects and maximize chances of achieving sustained virologic response (SVR). All patients achieved SVR despite the drug–drug interactions and there were no safety concerns. In patients facing this unique clinical quandary, the use of CYP and drug transport inhibitors appears to be a safe and possible strategy.
Subject
Pharmacology (medical),Pharmacology
Reference25 articles.
1. Epclusa [package insert]: Gilead; 2022.https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf. Accessed March 20 2023.
2. Mavyret [package insert]. Abbvie; 2021.https://www.rxabbvie.com/pdf/mavyret_pi.pdf. Accessed March 20 2023.
3. Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study